Inve India ▾

Dr. Agarwal's Health Care share price & results

Dr. Agarwal's Health Care Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's largest eye care chain, offering surgeries, consultations, opticals and eye-care pharma products.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue383 ₹ crore+26.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin25.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit17.0 ₹ crore+70.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity7.56 %+1.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.84 %+0.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)22.95 %−6.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 8 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

Dr. Agarwal's Health Care Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (5 achieved, 3 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
New Facilitiesopening about close to 45 to 50 facilities this year
Call transcript, Q3 FY25 · 17 Feb 2025		Q3 FY25Q1 FY27:No new information on past promise.
Call transcript, Q1 FY27 · 4 Aug 2026		Achieved
Cathedral Road Flagship Operationalsometime early FY 2026 to begin operations
Call transcript, Q3 FY25 · 17 Feb 2025		Q3 FY25Q1 FY27:No specific update provided on the Chennai flagship facility timeline.
Call transcript, Q1 FY27 · 4 Aug 2026		Ghosted
Merger Completionwithin a time span of 3 years and ideally sooner
Call transcript, Q3 FY25 · 17 Feb 2025		Q3 FY25Q1 FY27:On track, management expects to close the merger around mid-November (Q3 FY27).
Call transcript, Q1 FY27 · 4 Aug 2026		On Track

Source: Inve Guidance Tracker for Dr. Agarwal's Health Care Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Dr. Agarwal's Health Care Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹476.6 +0.28% · +₹1.35

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −8.5% 1Y

₹400₹450₹500₹550Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 31 Oct 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 21 May 2026Q1 FY27 — 4 Aug 2026

1Y: ₹520.85 on 24 Oct 2025 → ₹476.6. High ₹560.7 (10 Aug 2026), low ₹406.55 (30 Mar 2026).

Previous close
₹475.25
Market cap
₹15.1k Cr
52-week range
₹406.55 – ₹560.7
One year
−8.26%
Price to earnings (TTM to Jun 2026)
102.36×
Return on equity (TTM to Jun 2026)
7.56%

Overview

Symbol
NSE:AGARWALEYE
Exchange
NSE
Currency
INR

What Dr. Agarwal's Health Care Limited does

Based on the company's own presentations, annual report and earnings calls.

Dr. Agarwal's Health Care Limited runs an integrated, end-to-end eye care network across India and Africa, delivering cataract, refractive and other ophthalmic surgeries, doctor consultations and diagnostics, and non-surgical treatments, alongside in-house sale of opticals, contact lenses and eye-care pharmaceutical products. It operates on an asset-light, hub-and-spoke model with primary facilities as the first point of patient contact feeding into secondary and tertiary surgical centres (including Centres of Excellence) that handle complex cataract, retinal, corneal and refractive procedures. The company grows through a mix of organic greenfield facility launches and acquisitions of existing eye hospitals/clinics, which it integrates onto standardised clinical protocols and its in-house Neo hospital management system. It also trains clinical talent through an in-house medical college offering DNB and fellowship programmes.

Segments

  • Surgeries
  • Diagnosis, Consultations & Others
  • Opticals, Contact Lenses & Accessories
  • Eye Care Related Pharma Products
Eye care facilities
288 (as of March 2026)
Geographic footprint
155 cities across 14 states and 5 union territories in India, plus operations in 9 African countries (Ghana, Uganda, Kenya, Rwanda, Tanzania, Mozambique, Zambia, Mauritius, Madagascar)
Doctors
968
Paramedical staff
2,189
Patients served (FY26)
3,009,000+
Surgeries performed (FY26)
323,000+
Founded 1957Employees 6,118 (March 31, 2025) Company website

How the price took the results

close before → close after

Q1 FY27
+2.1%
4 Aug
Q4 FY26
+4.7%
21 May
Q3 FY26
+1.0%
4 Feb
Q2 FY26
−2.4%
31 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Dr. Agarwal's Health Care Limited

Free account: one company. Everything above stays public.

Write why you follow Dr. Agarwal's Health Care Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Dr. Agarwal's Health Care Limited

Guides on how to read this kind of business and the numbers that matter.